Press release

Interim Report 1 January - 30 September 2009

- In the Phase II study of the product candidate TB-402 for the prevention of thrombosis, the treatment of patients in the third and final 100 patient cohort was started in September.

- In August the U.S. Food & Drug Administration (FDA) approved the Company's application to initiate Phase I studies of the product candidate BI-505 for the treatment of Multiple Myeloma.

- All patients have been treated in the Phase I study with repeated doses of TB-403 for patients with advanced cancer.

- Technology transfer under the terms of the alliance with Roche on product candidate TB-403 triggered during the first quarter a success fee of EUR 5 million to BioInvent and ThromboGenics.

- The phase I trial of BI-204 was completed in the second quarter. The product candidate for the prevention of secondary events in patients with cardiovascular disease was well tolerated. The drug is being co-developed with Genentech, a wholly-owned member of the Roche Group.

- During the third quarter an agreement was reached with Mitsubishi Tanabe Pharma Corp. for research and development of antibody drugs.

- Net revenues for January - September 2009: SEK 60.6 million (229.0 including initial milestone payment of 187.6 relating to TB-403).

- Current investments together with cash and bank as of 30 September 2009: SEK 113.8 million (252.7).

- Cash flow from current operations and investment activities for January - September 2009: SEK -98.6 million (35.9).

- Loss after tax for January - September 2009 amounted to SEK -130.8 million (61.6) and the profit after tax per share was SEK -2.35 (1.11).